Pharma News

Who’s saying what? Regenerative Medicine mentions in company filings of pharmaceutical industry decreased by 24% in Q1 2023

The global pharmaceutical industry experienced a 24% drop in company filings mentions of regenerative medicine in Q1 2023 compared with the previous quarter, with the highest share accounted for by Sarepta Therapeutics with 20% year-on-year decrease, according to GlobalData’s analysis of over 578 pharmaceutical company filings. GlobalData’s Regenerative Medicine in Medical thematic intelligence report provides an overview of the current landscape, including healthcare, technology, regulatory, macroeconomic trends, and key players. Buy the report here.

Notably, regenerative medicine was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of social and metaverse, according to GlobalData.

!function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0!==a.data[“datawrapper-height”]){var e=document.querySelectorAll(“iframe”);for(var t in a.data[“datawrapper-height”])for(var r=0;r<e.length;r++)if(e[r].contentWindow===a.source){var i=a.data["datawrapper-height"][t]+"px";e[r].style.height=i}}}))}();

Of the top leading companies in the pharmaceutical industry, Sarepta Therapeutics had the greatest increase in references for regenerative medicine in Q1 2023, compared with the previous quarter. GlobalData identified 51 regenerative medicine-related sentences in the company’s filings – 2% of all sentences – and an increase of 100% in Q1 2023 compared with Q1 2022. Novartis’s mentions of regenerative medicine rose by 100% to 38 and Charles River Laboratories International’s by 100% to 35 and Gilead Sciences’s by 100% to 32 and Vertex Pharmaceuticals’s by 100% to 31.

!function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0!==a.data[“datawrapper-height”]){var e=document.querySelectorAll(“iframe”);for(var t in a.data[“datawrapper-height”])for(var r=0;r<e.length;r++)if(e[r].contentWindow===a.source){var i=a.data["datawrapper-height"][t]+"px";e[r].style.height=i}}}))}();

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for regenerative medicine in Q1 2023 was 104.

!function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0!==a.data[“datawrapper-height”]){var e=document.querySelectorAll(“iframe”);for(var t in a.data[“datawrapper-height”])for(var r=0;r<e.length;r++)if(e[r].contentWindow===a.source){var i=a.data["datawrapper-height"][t]+"px";e[r].style.height=i}}}))}();

For further understanding of GlobalData’s Regenerative Medicine in Medical – Thematic Research buy the report here.

Source link
#Whos #Regenerative #Medicine #mentions #company #filings #pharmaceutical #industry #decreased

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *